Martinez-Diaz et. al., “Preparation and enantiomeric purity determination of new chiral C2 building blocks based on the 4-amino-1,2,4-amino-1,2,4-triazole unit”, Tetrahedron: Assymetry, 1994, 5(7), 1291-6.* |
Lancelot, et. al., “Pyrrolo[1,2-d][1,2,4]triazines. I. Pyrrole derivatives”, J. Heterocycl. Chem. (1980), 17(4), 625-9.* |
CA Reference 122:10548m “Preparation and enantiomeric purity determination of new chiral C2 building blocks based on the 4-amino-1,2-4-triazole unit”, Martinez′-Diaz, et. al., p. 1174, vol. 122, 1995.* |
Borg, et al.: “Synthesis of 1,2,4-Oxadiazole-, 1,3,4-Oxadiazole-, and 1,2,4-Triazole-Derived Dipeptidomimetics” J. Org. Chem. 1995, vol. 60, pp. 3112-3120. |
Liang, G. et al: “An Improved Oxadiazole Synthesis Using Peptide Coupling Reagents” Tetrahedron Letters, vol. 37, pp. 6627-6630, 1996. |
Juliano, L. et al: “Amino Acids and Peptides.XVI. Synthesis of Ng-Tosylarginyl Peptide Derivatives-Observation of Lactam Formation of Arginyl Residue” Chem. Pharm. Bull. 35 No. 6 pp. 2250-2553. |
Hamilton, et al.: “Neuroimmunophilin Ligands as Novel Therapeutics for the Treatment of Degenerative Disorders of the Nervous System” Current Pharm. Design, Vo.3 No. 4, 1997, pp. 405-428. |
Holt, D. A. et al.: “Structure-Activity Studies of Synthetic FKBP Ligands as Peptidyl-Prolyl Isomerase Inhabitors”, Bioorganic & Medicinal Chemistry Letters, GB, Oxford, vol. 4, No. 2, 1994, pp. 315-320. |
G. S. Hamilton et al. “FKBP12-Binding Domain Analogues of FK506 are Potent, Nonimmunosuppressive Neurotrophic Agents in vitro and and Promote Recovery in a Mouse Model of Parkinson's Disease” Bioorganic & Medicinal Chemistry Letters, GB, Oxford, vol. 7, No. 13, 1997, pp. 1785-1790. |
Snyder, S. H. et al.: “Neural Action of Immunophilin Ligands” Trends in Pharmacological Sciences, vol. 19, No. 1, 1998, pp. 21-26. |
International Search Report Application No. PCT/US00/16221 dated Mar. 28, 2001. |
Roberta Brinton et al. “Advances and Challenges in the Prevention . . . ” Pharm. Res. 1998, 15, 386-398. |
Rajesh Pahwa et al. “Advances in the Treatment of Parkinson's Disease”, Drugs Tody, 1998, 34, 95-105. |
Erik Louvel et al., “Therapeutic Advances in Amyotrohic . . . ” Trends Pharmacol. Sci 1997, 18, 196-203. |
Geert-Jan Biessels et al., “Diabetic Neuropathy: Pathogenesis and Current . . . ”Neurosci. Res. Commun., 1997, 20, 1-10. |
D.R. Tomlinson et al., “Role of Neurotrophins in Diabetic Neuropathy . . . ”, Diabetes, 1997, 46(Suppl. 2) S43-S-49. |
Brinton, R.D. and Yamazaki, R.S., Pharm. Res., 1998, 15, 386-398. |
Pahwa, R. and Koller, W.C., Drugs Today, 1998, 34, 95-105. |
Louvel, E., Hugon, J. and Doble, A., Trends Pharmacol. Sci., 1997, 18, 196-203. |
Biessels, G. J. and Van Dam, P.S., Neurosci. Res. Commun., 1997, 20, 1-10. |
Tomlinson, D.R., Fernyhough, P. and Diemel, L.T., Diabetes, 1997, 46(suppl. 2) S43-S-49. |
Hamilton, G.S., Chem. Ind., (London) 1998, 4, 127-132. |
Ebadi, M., et al., Neurochem. Int., 1997, 30, 347-374. |
Lyons, W. E., et al. (Proc. Natl. Acad.Sci., 1994, 91(8), 3191-5). |
Holt, Dennis A., et al. (Bioorg. Med Chem., 1998 6(8) 1309-1335. |